Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New POC Malaria Test 12 Times Faster Than Currently Available Laboratory-Based Tests

By LabMedica International staff writers
Posted on 01 Mar 2024

Malaria continues to pose a major global health threat, with approximately 247 million cases and over 600,000 deaths annually, predominantly in sub-Saharan Africa. More...

Particularly alarming is cerebral malaria, a severe form of the disease, which has a high mortality rate, especially among children under five. The existing rapid diagnostic tests (RDTs) for malaria offer a basic positive or negative result, but often fail to detect asymptomatic infections and lack the sensitivity required for early detection of severe cases. More sensitive molecular assays that exist are costly, time-consuming, and need specialized skills and equipment, rendering them unsuitable for widespread application in areas with limited resources. In light of these challenges, researchers have now developed a new test for diagnosing malaria that is both rapid and accurate. This POC rapid malaria test offers a significant improvement over traditional tests and will be especially beneficial for rural areas with limited healthcare facilities.

Researchers at Rice University (Houston, TX, USA) developed a microfluidic point-of-care (mPOC) immunoassay for quantifying a malaria parasite biomarker, Plasmodium falciparum histidine-rich protein 2 (PfHRP2), in whole blood. This device provides dual diagnostic modes to detect PfHRP2 at low and high concentrations, making it versatile for various diagnostic needs, such as identifying asymptomatic infections and predicting disease progression. The test produces results in just 15 minutes, which can be easily accessed via a smartphone app developed by the researchers. Field tests in Malawi revealed that the mPOC immunoassay matches the accuracy of the standard PfHRP2 enzyme-linked immunosorbent assay (ELISA), but is 12 times quicker and simpler to operate. This advancement in malaria diagnostics, especially for cerebral malaria, holds the promise of early detection and prompt treatment of severe cases, potentially saving numerous lives.

“The mPOC immunoassay was designed to be simple, accurate and field-deployable, making it suitable for use in rural and remote health centers in sub-Saharan Africa,” said mechanical engineer Peter Lillehoj of Rice’s Brown School of Engineering who led the research team. “Unlike traditional tests, this device does not require plasma separation, pipetting, complicated sample processing or long incubations, making it easy to use even by minimally trained health care providers.”

“In areas with limited access to health care facilities, our test could be a game-changer,” added Lillehoj. “It can help health care providers quickly identify and treat severe cases, potentially saving lives. By enabling early detection and appropriate management of malaria cases, we can reduce the burden of the disease and improve patient outcomes in Africa and beyond.”

Related Links:
Rice University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.